Skip to main content
Year archive

Can-Fite BioPharma Ltd. — 2023 filings

All 170 regulatory filings released by Can-Fite BioPharma Ltd. (CANF) in 2023, sourced directly from the official regulator.

170 Filings
2023 Period
2023 filings (170)
Filing Released Lang
AMENDMENT NO. 1 TO FORM F-3
Regulatory Filings
2023-12-28 English
Amendment No. 1 to Resale Registration Statement on Form F-3
Capital/Financing Update
2023-12-28 English
Amendment No. 1 to Resale Registration Statement on Form F-3
Report Publication Announcement
2023-12-28 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-12-20 English
The Anti-Obesity Effect of Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
Regulatory Filings
2023-12-20 English
The Anti-Obesity Effect of Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
Report Publication Announcement
2023-12-20 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-12-18 English
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
Regulatory Filings
2023-12-18 English
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
Regulatory Filings
2023-12-18 English
Resale Registration Statement on Form F-3
Capital/Financing Update
2023-12-12 English
Resale Registration Statement on Form F-3
Regulatory Filings
2023-12-12 English
REGISTRATION STATEMENT
Regulatory Filings
2023-12-12 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-12-04 English
Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
Regulatory Filings
2023-12-04 English
Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
Report Publication Announcement
2023-12-04 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-11-30 English
Third Quarter 2023 Financial Results and Clinical Update
Interim / Quarterly Report 9M 2023
2023-11-30 English
Third Quarter 2023 Financial Results and Clinical Update
Report Publication Announcement
2023-11-30 English
PROSPECTUS SUPPLEMENT
Regulatory Filings
2023-11-22 English
PROSPECTUS SUPPLEMENT (To Prospectus dated February 10, 2023)
Capital/Financing Update
2023-11-22 English
PROSPECTUS SUPPLEMENT (To Prospectus dated February 10, 2023)
Report Publication Announcement
2023-11-22 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-11-22 English
FORM 6-K-Exercise of Warrants by an institutional investor
Regulatory Filings
2023-11-22 English
FORM 6-K-Exercise of Warrants by an institutional investor
Report Publication Announcement
2023-11-22 English
CURRENT REPORT
Regulatory Filings
2023-11-21 English
Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds
Regulatory Filings
2023-11-21 English
Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds
Report Publication Announcement
2023-11-21 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-11-21 English
omplete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson
Regulatory Filings
2023-11-21 English
omplete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson
Report Publication Announcement
2023-11-21 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-11-01 English
FORM 6-K-Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track
Regulatory Filings
2023-11-01 English
FORM 6-K-Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track
Report Publication Announcement
2023-11-01 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-10-30 English
Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action
Regulatory Filings
2023-10-30 English
Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action
Report Publication Announcement
2023-10-30 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-10-26 English
Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
Regulatory Filings
2023-10-26 English
Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
Report Publication Announcement
2023-10-26 English
Can Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies
Regulatory Filings
2023-10-10 English
Can Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies
Report Publication Announcement
2023-10-10 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-10-10 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-09-27 English
Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR
Regulatory Filings
2023-09-27 English
Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR
Report Publication Announcement
2023-09-27 English
Regulatory Filings 2023
Regulatory Filings
2023-09-13 English
Regulatory Filings 2023
Regulatory Filings
2023-09-11 English
Regulatory Filings 2023
Regulatory Filings
2023-09-11 English
Regulatory Filings 2023
Regulatory Filings
2023-09-08 English
Investor Presentation
Investor Presentation
2023-09-07 English
Investor Presentation
Report Publication Announcement
2023-09-07 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-09-07 English
POST-EFFECTIVE AMENDMENT NO. 5 TO FORM F-1
Regulatory Filings
2023-09-01 English
REGISTRATION STATEMENT
Regulatory Filings
2023-09-01 English
F-3 Shelf Renewal
Capital/Financing Update
2023-09-01 English
F-3 Shelf Renewal
Capital/Financing Update
2023-09-01 English
FORM F-1 -REGISTRATION STATEMENT
Capital/Financing Update
2023-09-01 English
FORM F-1 -REGISTRATION STATEMENT
Report Publication Announcement
2023-09-01 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-08-31 English
Financial results for the six months ended June 30, 2023 and updates on its drug development programs and an unaudited interim condensed consolidated financial statements as of June 30, 2023.
Interim / Quarterly Report H1 2023
2023-08-31 English
Financial results for the six months ended June 30, 2023 and updates on its drug development programs and an unaudited interim condensed consolidated financial statements as of June 30, 2023.
Report Publication Announcement H1 2023
2023-08-31 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-08-24 English
Can-Fite Enters Rare Genetic Disease FieldBased on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious inTreating Lowe Syndrome
Regulatory Filings
2023-08-24 English
Can-Fite Enters Rare Genetic Disease FieldBased on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious inTreating Lowe Syndrome
Report Publication Announcement
2023-08-24 English
Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis
Regulatory Filings
2023-08-18 English
Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis
Report Publication Announcement
2023-08-18 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-08-18 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-08-07 English
Results of Annual Shareholders Meeting held on August 7, 2023
Regulatory Filings
2023-08-07 English
Results of Annual Shareholders Meeting held on August 7, 2023
AGM Information
2023-08-07 English
The Annual General Meeting was adjourned due to lack of quorum and will be reconvened on Monday, August 7, 2023 at 3:00p.m., Israel time
Regulatory Filings
2023-07-31 English
The Annual General Meeting was adjourned due to lack of quorum and will be reconvened on Monday, August 7, 2023 at 3:00p.m., Israel time
Report Publication Announcement
2023-07-31 English
FORM 6-K
Regulatory Filings
2023-07-31 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-07-17 English
Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
Regulatory Filings
2023-07-17 English
Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
Report Publication Announcement Q2 2023
2023-07-17 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-06-29 English
U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan
Regulatory Filings
2023-06-29 English
U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan
Report Publication Announcement
2023-06-29 English
2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 31, 2023
Proxy Solicitation & Information Statement
2023-06-27 English
2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 31, 2023
Proxy Solicitation & Information Statement
2023-06-27 English
2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 31, 2023
AGM Information
2023-06-27 English
NOTICE OF 2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 31, 2023
AGM Information
2023-06-23 English
NOTICE OF 2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 31, 2023
Report Publication Announcement
2023-06-23 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-06-23 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-06-13 English
Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson
Regulatory Filings
2023-06-13 English
Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson
Report Publication Announcement
2023-06-13 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-06-01 English
1 Reports First Quarter 2023 Financial Results & Provides Clinical Update
Interim / Quarterly Report Q1 2023
2023-06-01 English
1 Reports First Quarter 2023 Financial Results & Provides Clinical Update
Report Publication Announcement
2023-06-01 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-05-30 English
Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
Regulatory Filings
2023-05-30 English
Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
Report Publication Announcement
2023-05-30 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-05-09 English
Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
Regulatory Filings
2023-05-09 English
Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
Regulatory Filings
2023-05-09 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-05-02 English
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
Regulatory Filings
2023-05-02 English
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
Report Publication Announcement
2023-05-02 English
Regulatory Filings 2023
Regulatory Filings
2023-04-25 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-04-24 English
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
Board/Management Information
2023-04-24 English
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
Report Publication Announcement
2023-04-24 English
POST-EFFECTIVE AMENDMENT NO. 4 TO FORM F-1
Regulatory Filings
2023-04-21 English
REGISTRATION STATEMENT
Regulatory Filings
2023-04-21 English
FORM S-8-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
Share Issue/Capital Change
2023-04-21 English
FORM S-8-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
Regulatory Filings
2023-04-21 English
FORM F-1 - Post-Effective Amendment
Capital/Financing Update
2023-04-21 English
FORM F-1 - Post-Effective Amendment
Report Publication Announcement
2023-04-21 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-04-10 English
EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
Regulatory Filings
2023-04-10 English
EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
Regulatory Filings
2023-04-10 English
POST-EFFECTIVE AMENDMENT NO. 3 TO FORM F-1
Regulatory Filings
2023-03-31 English
Post-effective amendment to Form F-1
Transaction in Own Shares
2023-03-31 English
Post-effective amendment to Form F-1
Regulatory Filings
2023-03-31 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-03-30 English
ANNUAL REPORT
Annual Report FY 2022
2023-03-30 English
Financial results for the year ended December 31, 2022
Annual Report FY 2022
2023-03-30 English
Financial results for the year ended December 31, 2022
Report Publication Announcement
2023-03-30 English
Reports 2022 Financial Results & Provides Clinical Update
Earnings Release FY 2022
2023-03-30 English
Reports 2022 Financial Results & Provides Clinical Update
Report Publication Announcement
2023-03-30 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-03-13 English
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
Regulatory Filings
2023-03-13 English
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
Report Publication Announcement
2023-03-13 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-02-22 English
Results of general meeting held on February 22, 2023
Regulatory Filings
2023-02-22 English
Results of general meeting held on February 22, 2023
Report Publication Announcement
2023-02-22 English
The Company’s Special General Meeting was adjourned due to lack of quorum, and will be reconvened on February 22, 2023 -FORM 6K
Regulatory Filings
2023-02-21 English
The Company’s Special General Meeting was adjourned due to lack of quorum, and will be reconvened on February 22, 2023 -FORM 6K
Proxy Solicitation & Information Statement
2023-02-21 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-02-21 English
The Company’s Special General Meeting was adjourned due to lack of quorum, and will be reconvened on February 22, 2023 -FORM 6K
Regulatory Filings
2023-02-21 English
The Company’s Special General Meeting was adjourned due to lack of quorum, and will be reconvened on February 22, 2023 -FORM 6K
Regulatory Filings
2023-02-21 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-02-14 English
FORM 6-K -Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo
Regulatory Filings
2023-02-14 English
FORM 6-K -Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo
Report Publication Announcement
2023-02-14 English
Regulatory Filings 2023
Regulatory Filings
2023-02-13 English
424b3- Prospectus Supplement
Regulatory Filings
2023-02-11 Hebrew (modern)
424b3- Prospectus Supplement
Regulatory Filings
2023-02-11 English
AMENDMENT TO F-1-REGISTRATION STATEMENT
Regulatory Filings
2023-02-11 Hebrew (modern)
AMENDMENT TO F-1-REGISTRATION STATEMENT
Report Publication Announcement
2023-02-11 English
PROSPECTUS SUPPLEMENT
Regulatory Filings
2023-02-10 English
AMENDMENT NO. 1 TO FORM F-1
Regulatory Filings
2023-02-10 English
Regulatory Filings 2023
Regulatory Filings
2023-02-08 English
Regulatory Filings 2023
Regulatory Filings
2023-02-06 English
FORM F-1 -Registration statement of 955,909,800 Ordinary Shares represented by 3,186,366 American Depositary Shares
Capital/Financing Update
2023-02-01 English
FORM F-1 -Registration statement of 955,909,800 Ordinary Shares represented by 3,186,366 American Depositary Shares
Regulatory Filings
2023-02-01 English
REGISTRATION STATEMENT
Regulatory Filings
2023-01-31 English
Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed
Regulatory Filings
2023-01-24 English
Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed
Report Publication Announcement
2023-01-24 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-01-24 English
Notice of extraordinary meeting that will be held on February 21, 2023, To approve a renewed version of the Company’s Compensation Policy, To cancel the par value of the Company’s shares
Proxy Solicitation & Information Statement
2023-01-14 English
Notice of extraordinary meeting that will be held on February 21, 2023, To approve a renewed version of the Company’s Compensation Policy, To cancel the par value of the Company’s shares
Proxy Solicitation & Information Statement
2023-01-14 English
Notice of extraordinary meeting that will be held on February 21, 2023, To approve a renewed version of the Company’s Compensation Policy, To cancel the par value of the Company’s shares
Proxy Solicitation & Information Statement
2023-01-14 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update
2023-01-14 English
PROSPECTUS SUPPLEMENT
Regulatory Filings
2023-01-14 English
6-K-Institutional Offering
Regulatory Filings
2023-01-14 English
6-K-Institutional Offering
Report Publication Announcement
2023-01-14 English
Prospectus Supplement
Capital/Financing Update
2023-01-14 English
Prospectus Supplement
Capital/Financing Update
2023-01-14 English
PROSPECTUS SUPPLEMENT
Regulatory Filings
2023-01-13 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-01-13 English
PROSPECTUS SUPPLEMENT
Regulatory Filings
2023-01-13 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-01-13 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-01-11 English
Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement
Capital/Financing Update
2023-01-11 English
Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement
Capital/Financing Update
2023-01-11 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2023-01-10 English
Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow
Regulatory Filings
2023-01-10 English
Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow
Report Publication Announcement
2023-01-10 English